| Drug Name |
Alfuzosin hydrochloride |
| Drug ID |
BADD_D00070 |
| Description |
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70.[A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] |
| Indications and Usage |
For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
G04CA01 |
| DrugBank ID |
DB00346
|
| KEGG ID |
D01692
|
| MeSH ID |
C047638
|
| PubChem ID |
71764
|
| TTD Drug ID |
D0H1YQ
|
| NDC Product Code |
46014-1018; 14501-0003; 13668-021; 63629-2354; 65862-249; 76282-302; 29300-155; 63278-0500; 64679-738; 63629-7907; 61919-349; 63629-2353; 53747-019; 71335-1529; 63629-9155; 69097-844; 57237-114; 66039-826; 65862-206; 70934-306; 65977-0023; 47335-956; 43353-945 |
| Synonyms |
alfuzosin | alphuzosine | N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide | alfusozine | alfuzosin hydrochloride | UroXatral | Benestan | Urion | Xatral | Alfetim |
